PMGC (ELAB)
Market Price (3/30/2026): $3.33 | Market Cap: $73,323Sector: Health Care | Industry: Biotechnology
PMGC (ELAB)
Market Price (3/30/2026): $3.33Market Cap: $73,323Sector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11138% | Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -162% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2129% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 128% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2163%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2301% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Health Data Analytics, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18224% | |
| High stock price volatilityVol 12M is 551% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 150% | ||
| Key risksELAB key risks include [1] sustained unprofitability with a five-year history of declining earnings and [2] a significant cash burn rate creating a high risk of shareholder dilution. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11138% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 128% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Advanced Diagnostics, Health Data Analytics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -122%, 3Y Excs Rtn is -162% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.1 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2129% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -2163%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -2301% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -18224% |
| High stock price volatilityVol 12M is 551% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 150% |
| Key risksELAB key risks include [1] sustained unprofitability with a five-year history of declining earnings and [2] a significant cash burn rate creating a high risk of shareholder dilution. |
Qualitative Assessment
AI Analysis | Feedback
1. Multiple Reverse Stock Splits to Maintain Listing.
PMGC Holdings (ELAB) implemented two significant reverse stock splits during the specified period, signaling struggles to maintain its share price and exchange listing. A 1-for-4 reverse stock split became effective on January 6, 2026. This was followed by another 1-for-6 reverse stock split, effective March 10, 2026. Historically, reverse stock splits for PMGC Holdings have resulted in an average 24-hour negative price movement of -16.98%.
2. Persistent Negative Earnings and Weak Financial Performance.
The company reported significant negative earnings, contributing to a lack of investor confidence. For Q3 2025, reported on November 14, 2025, PMGC Holdings announced an earnings per share (EPS) of -$118.80 on quarterly revenue of $0.29 million. The company's trailing EPS stood at -$400.97. Furthermore, for the trailing 12 months ending September 30, 2025, PMGC Holdings reported earnings of -$6.7 million. Its Return on Equity was -82.9%, and Return on Assets was -63.5%, indicating poor profitability and asset utilization.
Show more
Stock Movement Drivers
Fundamental Drivers
The -98.7% change in ELAB stock from 11/30/2025 to 3/29/2026 was primarily driven by a -98.7% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 127.44 | 1.67 | -98.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 9.8 | 0.1 | -98.7% |
| Shares Outstanding (Mil) | 0 | 0 | 0.0% |
| Cumulative Contribution | -98.7% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ELAB | -98.7% | |
| Market (SPY) | -5.3% | 3.9% |
| Sector (XLV) | -8.7% | -3.8% |
Fundamental Drivers
The -98.8% change in ELAB stock from 8/31/2025 to 3/29/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 136.08 | 1.67 | -98.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 0.1 | |
| Shares Outstanding (Mil) | 0 | 0 | -32.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ELAB | -98.8% | |
| Market (SPY) | 0.6% | 3.6% |
| Sector (XLV) | 5.2% | -2.3% |
Fundamental Drivers
The -99.8% change in ELAB stock from 2/28/2025 to 3/29/2026 was primarily driven by a -142.5% change in the company's P/S Multiple.| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 732.06 | 1.67 | -99.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | -1 | 0 | -128.2% |
| P/S Multiple | -0.3 | 0.1 | -142.5% |
| Shares Outstanding (Mil) | 0 | 0 | -98.1% |
| Cumulative Contribution | -99.8% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ELAB | -99.8% | |
| Market (SPY) | 9.8% | 5.8% |
| Sector (XLV) | -2.1% | 1.2% |
Fundamental Drivers
nullnull
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| ELAB | ||
| Market (SPY) | 69.4% | 5.4% |
| Sector (XLV) | 18.4% | 0.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ELAB Return | - | - | -46% | -99% | -97% | -95% | -100% |
| Peers Return | 12% | -2% | 16% | 3% | 11% | -17% | 21% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| ELAB Win Rate | - | - | 0% | 25% | 17% | 0% | |
| Peers Win Rate | 53% | 57% | 50% | 53% | 57% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| ELAB Max Drawdown | - | - | -49% | -99% | -98% | -98% | |
| Peers Max Drawdown | -31% | -32% | -26% | -19% | -38% | -22% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: EOLS, ABBV, LLY, MCRB, PRLB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
ELAB has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to EOLS, ABBV, LLY, MCRB, PRLB
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About PMGC (ELAB)
AI Analysis | Feedback
Here are 1-2 brief analogies for ELAB:
The Augustinus Bader of physician-dispensed skincare, leveraging proprietary exosome technology.
Think of it as SkinCeuticals or ZO Skin Health, but specializing in advanced stem cell exosome-based formulations for professional aesthetic use.
AI Analysis | Feedback
- Topical Skincare Products with Elevai Exosomes™: Physician-dispensed cosmetic solutions infused with proprietary stem cell-derived exosomes, designed to topically enhance the appearance of skin and address common cosmetic conditions.
AI Analysis | Feedback
PMGC (ELAB) primarily operates on a business-to-business (B2B) model. Its major customers are:
- Physicians
- Medical aesthetics practices and clinics
These customers acquire ELAB's proprietary stem cell-derived Elevai Exosomes™ skincare products for dispensing to their patients and clients. The provided background information does not list the specific names of these customer companies, nor are these types of businesses typically public entities with stock symbols.
AI Analysis | Feedback
nullAI Analysis | Feedback
Graydon Bensler, Chief Executive Officer & Chief Financial Officer
Graydon Bensler was appointed as the non-employee Chief Executive Officer of PMGC Holdings Inc. (formerly Elevai Labs Inc.) on June 21, 2024, while also continuing to serve as the Chief Financial Officer until a successor is identified. He has served as a Director of Redwood AI Corp. and has been an Independent Director of AquaBounty Technologies, Inc. since October 28, 2025. He previously served as a Director of Onco-Innovations Limited.
Dr. Jordan R. Plews, Co-Founder, Head of Elevai Skincare and Elevai Biosciences
Dr. Jordan R. Plews is a co-founder of Elevai Labs, Inc. He served as the Chief Executive Officer until his resignation on June 21, 2024, and now leads the company's subsidiaries, Elevai Skincare and Elevai Biosciences. Dr. Plews has a background in biochemical engineering and stem cell research, having completed his undergraduate and doctoral studies in the UK and a postdoc at Stanford University. He transitioned into the biotech industry, where he created products for researchers and clinicians, and has experience working at companies like Pfizer and Beckton Dickinson. He holds seven filed patents and approximately 25 filed trademarks.
Braeden Lichti, Co-Founder & Non-Executive Chairman of the Board
Braeden Lichti is a co-founder of ELEVAI Labs and serves as the Non-Executive Chairman of the Board. He is also noted as the founder of one other company.
AI Analysis | Feedback
Regulatory Classification Risk
PMGC's core business revolves around "physician-dispensed skincare products" that are explicitly stated as "not drug products or considered regenerative medicine, nor have any of our products received FDA approval." The company markets these products as "topical cosmetic solutions" to "enhance the appearance of skin." A significant risk lies in the potential for regulatory bodies, such as the FDA, to reclassify their exosome-infused products from cosmetics to drugs or regenerative medicine. Such a reclassification would subject PMGC to substantially stricter regulations, requiring extensive and costly clinical trials, prolonged development timelines, and potential halts in sales until the necessary approvals are obtained. This could severely impact the company's operational model and financial viability.
Intellectual Property and Patent Risk
The company's competitive advantage is heavily reliant on its proprietary technology, specifically "proprietary stem cell-derived Elevai Exosomes™" and its "Precision Regenerative Exosome Technology™ (PREx™)" which utilizes "advanced patent-pending stem cell processing technology." The "patent-pending" status indicates that the intellectual property is not yet fully secured. There is a inherent risk that the applications for these patents may not be granted, or if granted, could be successfully challenged by competitors. A failure to secure or defend these patents could allow competitors to replicate or develop similar technologies, thereby eroding PMGC's unique market position and competitive advantage.
AI Analysis | Feedback
The primary clear emerging threat for ELAB is the potential reclassification of its "stem cell-derived Elevai Exosomes™" topical products by regulatory bodies (e.g., FDA) from cosmetics to drugs or biologics. ELAB explicitly states its products are "not drug products or considered regenerative medicine," "nor have any of our products received FDA approval," and "Our cosmetic products are not intended to prevent, treat or cure diseases or medical conditions." The use of "stem cell-derived" components that "may modulate and support these natural cellular processes" for cosmetic benefits introduces a gray area that regulators could scrutinize more intensely as the market for such advanced biotech-cosmetic hybrids grows. A reclassification would necessitate lengthy, costly, and uncertain drug approval processes, fundamentally disrupting ELAB's current business model, market access, and commercialization strategy.
AI Analysis | Feedback
PMGC (ELAB) operates in several addressable markets with substantial sizes globally and in North America, primarily through its physician-dispensed, exosome-infused topical skincare products aimed at enhancing skin appearance and addressing signs of aging.
Physician-Dispensed Skincare Market
- The global physician-dispensed skincare products market was valued at approximately USD 17.43 billion in 2026 and is projected to grow to about USD 34.32 billion by 2035, exhibiting a Compound Annual Growth Rate (CAGR) of 7.82%.
- In 2025, the global market for physician-dispensed cosmeceuticals was valued at USD 8.37 billion, with projections to reach USD 13.84 billion by 2031 at an 8.82% CAGR.
- North America holds a significant share of this market, accounting for over 35% in 2025. Another estimate indicates North America held a 40.08% share in 2025.
- Specifically, the U.S. physician-dispensed cosmeceuticals market size was valued at USD 3.28 billion in 2025 and is projected to reach USD 3.54 billion in 2026.
- Anti-aging products constitute a major segment within the physician-dispensed skincare market, representing over 40% of the total market share in 2025.
Exosomes Skincare Market
- The global exosomes skincare market was valued at USD 418.26 million in 2024 and is anticipated to reach USD 1,160.84 million by 2032, with a CAGR of 12.68%. Other estimates place the global market at USD 417.8 million in 2025, growing to USD 809.5 million by 2032 at a CAGR of 9.9%.
- North America is a leading region in the global exosomes skincare market, holding approximately 45% of the market share in 2024. The North American market alone was valued at USD 188.14 million in 2024 and is projected to reach USD 523.55 million by 2032.
- Anti-aging treatments are a dominant application segment within the exosome skincare market, driven by consumer demand for regenerative beauty solutions.
Anti-aging Products Market
- The broader global anti-aging products market was valued at USD 55.8 billion in 2023 and is projected to reach USD 108.5 billion by 2033, growing at a CAGR of 6.9%. Other estimates for the global market include USD 55.66 billion in 2025, reaching USD 107.61 billion by 2033 with an 8.9% CAGR.
- North America contributed significantly to the anti-aging products market, accounting for 35.99% of the global market revenue in 2025.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for PMGC (ELAB)
Over the next 2-3 years, PMGC (ELAB), formerly Elevai Labs, Inc., is expected to drive revenue growth through several key initiatives:
- Continued Growth of the Elevai Skincare Division: The core Elevai Skincare division has demonstrated significant sales milestones, including a record $300K monthly revenue in November 2024, representing a 65% increase over the preceding four-month average. This growth is attributed to a strategic overhaul by new management in Q3 2024, focusing on sales culture transformation, optimized budgets, and improved marketing strategies, which are expected to continue yielding positive results.
- Advancement and Commercialization of Biopharmaceutical Pipeline (Obesity Treatment): The company's subsidiary, Elevai Biosciences (now Northstrive Biosciences), is actively developing investigational products EL-22 and EL-32 for obesity treatment, specifically targeting muscle preservation during weight loss. The advancement of these candidates through preclinical and clinical trials, coupled with ongoing patent filings, represents a significant potential new revenue stream from the biopharmaceutical sector.
- Launch of New Skincare Products and Clinical Advancements: PMGC continues to invest in innovation within its aesthetic skincare portfolio. Clinical trials for products like Elevai Enfinity™ have shown improvements in skin firmness and wrinkle reduction, indicating a pipeline of new, advanced topical cosmetic solutions that can contribute to future sales.
- Strategic Acquisitions and Partnerships: The company's management has expressed a commitment to pursuing growth opportunities through strategic acquisitions and investments in the biotech, cosmetic, health, and wellness sectors. Additionally, collaborations, such as the one with Yuva Biosciences for obesity and diabetes treatments, and a pending acquisition of a U.S.-based IT custom packaging firm, are expected to expand the company's capabilities and market reach, thereby driving revenue.
- International Market Expansion: Elevai Labs reported over $213K in international revenue for 2023, indicating an expanding global footprint for its products. Continued penetration into new international markets for its physician-dispensed skincare offerings is anticipated to be a driver of incremental revenue growth.
AI Analysis | Feedback
nullLatest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| PMGC Stock 12-Day Losing Spree: Stock Falls 59% | 12/19/2025 | |
| PMGC Stock 11-Day Losing Spree: Stock Falls 57% | 12/18/2025 | |
| PMGC Stock Plummets 39% With 10-Day Losing Streak | 12/17/2025 | |
| PMGC Stock 9-Day Losing Spree: Stock Falls 38% | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ELAB.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 32.52 |
| Mkt Cap | 0.8 |
| Rev LTM | 415 |
| Op Inc LTM | 10 |
| FCF LTM | 27 |
| FCF 3Y Avg | 26 |
| CFO LTM | 34 |
| CFO 3Y Avg | 35 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.6% |
| Rev Chg 3Y Avg | 14.7% |
| Rev Chg Q | 13.2% |
| QoQ Delta Rev Chg LTM | 3.4% |
| Op Mgn LTM | 4.9% |
| Op Mgn 3Y Avg | 15.8% |
| QoQ Delta Op Mgn LTM | 0.9% |
| CFO/Rev LTM | 14.0% |
| CFO/Rev 3Y Avg | 17.0% |
| FCF/Rev LTM | 9.2% |
| FCF/Rev 3Y Avg | 5.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.8 |
| P/S | 2.5 |
| P/EBIT | 13.2 |
| P/E | 26.4 |
| P/CFO | 8.9 |
| Total Yield | 2.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -3.5% |
| D/E | 0.4 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.8% |
| 3M Rtn | -28.5% |
| 6M Rtn | -18.3% |
| 12M Rtn | -16.1% |
| 3Y Rtn | -2.1% |
| 1M Excs Rtn | -3.0% |
| 3M Excs Rtn | -21.6% |
| 6M Excs Rtn | -14.3% |
| 12M Excs Rtn | -27.2% |
| 3Y Excs Rtn | -61.6% |
Price Behavior
| Market Price | $1.67 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/21/2023 | |
| Distance from 52W High | -99.6% | |
| 50 Days | 200 Days | |
| DMA Price | $9.35 | $104.63 |
| DMA Trend | down | down |
| Distance from DMA | -82.1% | -98.4% |
| 3M | 1YR | |
| Volatility | 1,099.4% | 554.5% |
| Downside Capture | 6.45 | 3.84 |
| Upside Capture | -488.08 | -120.63 |
| Correlation (SPY) | 3.8% | 5.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 6.14 | 4.44 | 4.60 | 2.95 | 1.75 | 0.51 |
| Up Beta | 7.64 | 5.65 | 4.78 | 2.47 | 1.31 | -0.34 |
| Down Beta | 20.48 | 6.15 | 6.65 | 5.91 | 2.40 | 1.94 |
| Up Capture | -410% | -221% | -326% | -126% | -31% | -7% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 6 | 14 | 16 | 41 | 96 | 224 |
| Down Capture | 762% | 668% | 624% | 330% | 173% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 14 | 24 | 42 | 78 | 144 | 326 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELAB | |
|---|---|---|---|---|
| ELAB | -99.6% | 551.2% | 0.00 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 0.7% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 5.1% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 4.4% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | -2.0% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 4.4% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 11.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELAB | |
|---|---|---|---|---|
| ELAB | -91.6% | 380.6% | -0.55 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 0.3% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 5.4% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 6.4% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 4.4% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 5.0% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ELAB | |
|---|---|---|---|---|
| ELAB | -71.0% | 380.6% | -0.55 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 0.3% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 5.4% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 6.4% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 4.4% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 5.0% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 8.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.